Orthocell Secures Approval to sell Remplirâ„¢ to the U.S. Department of Defence Hospital Network

Orthocell logo (PRNewsfoto/Orthocell Ltd)

  • Orthocell receives approval for Remplirâ„¢ to be used across the United States Department of Defence (DoD) and Veterans Affairs (VA) hospital networks, comprising:
    • 51 DoD military hospitals; and
    • 170 Veterans Affairs (VA) medical centres
  • For context, Orthocell has already secured 32 Value Analysis Committee (VAC) approvals providing access to over 115 hospitals, with a further 57 VAC applications currently pending approval[1]
  • Orthocell will now leverage its existing U.S. distributor network to target military and VA surgeons operating within these hospital systems. The Company's distributor network currently covers 17 states
  • This approval comes at a time when Orthocell is seeing clear evidence of increasing commercialisation and revenue momentum in the U.S. market
  • Remplir has already demonstrated its value in conflict-related injuries in Ukraine, with multiple surgical procedures performed, highlighting its suitability for the types of trauma commonly encountered within military healthcare systems

PERTH, Australia, April 16, 2026 /PRNewswire/ -- Regenerative medicine company Orthocell Limited (ASX: OCC, "Orthocell" or the "Company") is pleased to announce it has secured approval for its Remplirâ„¢ nerve repair device to be used across the United States Department of Defence (DoD) and Veterans Affairs (VA) hospital networks.

(0) comments

Welcome to the discussion.

Keep it Clean. Please avoid obscene, vulgar, lewd, racist or sexually-oriented language.
PLEASE TURN OFF YOUR CAPS LOCK.
Don't Threaten. Threats of harming another person will not be tolerated.
Be Truthful. Don't knowingly lie about anyone or anything.
Be Nice. No racism, sexism or any sort of -ism that is degrading to another person.
Be Proactive. Use the 'Report' link on each comment to let us know of abusive posts.
Share with Us. We'd love to hear eyewitness accounts, the history behind an article.